Skip to content

Inspection prep notes · Quality system

Change control

Also called: change management

FDA looks less at whether a change control procedure exists than at whether actual changes went through it and were assessed, reviewed and closed on time. The findings below are quoted from warning letters and FDA 483s.

What inspectors cited

1No change control was opened and no risk assessment was done

When your customer requested a switch to pharmaceutical grade (b)(4) , you proceeded to repeat process validation without opening a change control per SOP KHIL/RB/QA/016/-R07, “Change Control.” You also failed to conduct a risk assessment of product that was in the U.S. market with non-pharmaceutical grade (b)(4) .

FDA Warning Letter · Kilitch Healthcare India Limited · 2024-04-09 · View document

Your firm failed to open a Change Control and conduct any associated risk assessments to existing data when individual user IDs and passwords were assigned to approved operators.

FDA 483 · Steriscience Specialties Private Limited · 2026-10-22 · View document

2The manufacturing process was changed without change control and not revalidated

For example, you changed the manufacturing process for (b)(4) to rephase the formulation without revalidation and outside of your change management system.

FDA Warning Letter · Bentley Laboratories LLC · 2026-09-29 · View document

In addition, in response to complaints regarding the viscosity of your (b)(4) formula, you changed the concentration of two ingredients without an adequate change control or justification for failing to validate this revised process.

FDA Warning Letter · Aruba Aloe Balm N.V. · 2024-05-28

3The impact of the change was not sufficiently assessed

The impact of the change to the specification for the inner cap (plug) used as part of your Artificial Tears container-closure system to a plug “with prehole” was not evaluated.

FDA Warning Letter · Global Pharma Healthcare Private Limited · 2023-11-14 · View document

Change Control PR1257198. opened on 6-Dec-2017 and closed on 21-Sep-2018, did not include a sufficient assessment on a critical material, used for manufacturing of Gammagard Liquid (GGL) and Hy Qvia.

FDA 483 · Baxalta Belgium Manufacturing S.A. · 2026-10-27 · View document

4The quality unit did not oversee change control

Your QU failed to ensure your firm follows your change control procedure. For example, since the last FDA inspection in March 2019, your firm implemented changes to your consumer complaints and drug product recalls procedures without following your change control procedure.

FDA Warning Letter · Sircle Laboratories, LLC · 2021-10-19

Your firm lacks adequate quality oversight to ensure Quality Risk Management Reports and change controls are thoroughly conducted and reviewed before approval.

FDA 483 · Hospira, Inc. · 2026-07-10 · View document

5Change controls were not completed on time

Your change control management system is not adequate and written procedures for change control are not followed, resulting in overdue changes and inaccurate records.

FDA 483 · Q-Med AB · 2026-10-22 · View document

We observed several change controls (including those listed below, not all-inclusive) being closed beyond their target completion dates and no extensions had been requested, which is contrary to SOP # CQA/0170 (Handling of Change Control Through TrackWise).

FDA 483 · Alkem Laboratories Limited · 2024-04-09 · View document

Questions to check against your procedures

  1. Is a change control opened, with a risk assessment, for changes such as switching a material grade or assigning user accounts?
  2. When a formulation, ingredient concentration or manufacturing process is changed, does it go through change control and revalidation?
  3. When a container-closure specification or a critical material is changed, is the impact assessed and recorded in the change control?
  4. Does the quality unit confirm that changes to procedures also follow the change control procedure?
  5. Does the quality unit oversee that change controls are thoroughly conducted and reviewed before approval?
  6. Are change controls past their target completion date formally extended or closed as the procedure requires?

Compiled by AI from public findings and checked by a person. Quotations are verbatim from the original documents; (b)(4) marks text redacted in the original. As of 2026-11-15.

Weekly Newsletter

New GMP inspection findings, every Monday

Every Monday we email the week's new inspection records from the FDA, EMA, Health Canada and MFDS, with a short summary of the week's regulatory news. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.